Herrera‐Acosta E, et al. - In this retrospective observational study, researchers contrasted the safety and effectiveness of secukinumab and ixekizumab used to treat moderate‐to‐severe psoriasis patients over 52 weeks. In addition, they identified which factors associated with prior biologic treatment influenced their efficacy, and analyzed data obtained at 12 weeks. For this analysis, they compared a group of the first 59 patients treated with secukinumab after its commercialization with another group of the first 29 patients treated with ixekizumab. No variations were observed in bio‐naïve or bio‐experienced patients between secukinumab and ixekizumab, except for a higher PASI 75 response at week 52 for ixekizumab in those patients with 2 or more previous biologics. With no statistically significant differences, secukinumab and ixekizumab have shown high safety and effectiveness.